Moawia Mohamed Ali ElhassanAssociate Professor at Gezira University and Consultant in Clinical and Radiation Oncology at Sudan Universal Hospital, shared the following post. linkedin:
“Deescalation of Adjuvant Therapy: Results from the Phase III neoCARHP Study in HER2+ Breast Cancer”
Phase III neoCARHP studyrecently published JCOneoadjuvant Taxanes and trastuzumab and pertuzumabwithout carboplatin (THP) for 6 cycles. Taxanes and trastuzumab and pertuzumaband Carboplatin (TCbHP) in achieving Stage II-III HER2+ pCR p Breast cancer with reduced toxicity.
PCR It was 64.1% in 65.9% in THP group and TCbHP group.
These findings contribute to the growing body of evidence that carboplatin can be safely omitted from neoadjuvant therapy for low to intermediate risk patients. HER2 positive breast cancer without compromising clinical results.
This “less is more” approach maintains clinical outcomes and improves patient outcomes.
This study mainly enrolled the following patients: Stage II (>2/3)Care should be taken when applying these results to more advanced cases. ”
title: Neoadjuvant taxane in combination with trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2-positive breast cancer: a randomized, non-inferiority phase III neoCARHP trial
author: Hong-Fei Gao, Guo-Lin Ye, Ying Lin, Qin Huang, MM, Jie Dong, MM, Ying Cao, MM, Yan-Xia Zhao, Qian-Jun Chen, Shi-Hui Ma, Jie Ouyang, Jin-Hui Ye, Hua-Wei Yang, Yuan-Qi Zhang, Yong-Cheng Zhang, Gang-Ling Zhang, MM, Wei Li, Yunjian. Zhang, Zhi-Yong Wu, Ying-Yi Lin, MM, Teng Zhu, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Hao Peng, Bo Chen, Yi-Tian Chen, Fei Ji, Min-Yi Cheng, Jie-Qing Li, Zefei Jiang, and Kun Wang.
please read study
See more featured articles Moawia Mohamed Ali Elhassan